Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): First results from CALGB trial 7980

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 512-512 ◽  
Author(s):  
C. L. Shapiro ◽  
S. Halabi ◽  
G. Gibson ◽  
D. J. Weckstein ◽  
J. Kirshner ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Adjuvant Chemotherapy ◽  
Bone Mineral ◽  
Premenopausal Women ◽  
Ovarian Failure ◽  
Mineral Density ◽  
First Results

scholarly journals Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809

2011 ◽  
Vol 47 (5) ◽  
pp. 683-689 ◽  
Author(s):  
C.L. Shapiro ◽  
S. Halabi ◽  
V. Hars ◽  
L. Archer ◽  
D. Weckstein ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Adjuvant Chemotherapy ◽  
Bone Mineral ◽  
Premenopausal Women ◽  
Ovarian Failure ◽  
Mineral Density

Ovarian Failure After Adjuvant Chemotherapy Is Associated With Rapid Bone Loss in Women With Early-Stage Breast Cancer

2001 ◽  
Vol 19 (14) ◽  
pp. 3306-3311 ◽  
Author(s):  
Charles L. Shapiro ◽  
Judith Manola ◽  
Meryl Leboff
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Alkaline Phosphatase ◽  
Adjuvant Chemotherapy ◽  
Bone Loss ◽  
Bone Mineral ◽  
Ovarian Failure ◽  
Mineral Density ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase

PURPOSE: We sought to evaluate the effects of chemotherapy-induced ovarian failure on bone loss and markers of skeletal turnover in a prospective longitudinal study of young women with breast cancer receiving adjuvant chemotherapy. PATIENTS AND METHODS: Forty-nine premenopausal women with stage I/II breast cancers receiving adjuvant chemotherapy were evaluated within 4 weeks of starting chemotherapy (baseline), and 6 and 12 months after starting chemotherapy with dual-energy absorptiometry and markers of skeletal turnover osteocalcin and bone-specific alkaline phosphatase. Chemotherapy-induced ovarian failure was defined as a negative pregnancy test, greater than 3 months of amenorrhea, and a follicle-stimulating hormone ≥ 30 MIU/mL at the 12-month evaluation. RESULTS: Among the 35 women who were defined as having ovarian failure, highly significant bone loss was observed in the lumbar spine by 6 months and increased further at 12 months. The median percentage decrease of bone mineral density in the spine from 0 to 6 months and 6 to 12 months was −4.0 (range, −10.4 to +1.0; P = .0001) and −3.7 (range, −10.1 to 9.2; P = .0001), respectively. In contrast, there were no significant decreases in bone mineral density in the 14 patients who retained ovarian function. Serum osteocalcin and bone specific alkaline phosphatase, markers of skeletal turnover, increased significantly in the women who developed ovarian failure. CONCLUSION: Chemotherapy-induced ovarian failure causes rapid and highly significant bone loss in the spine. This may have implications for long-term breast cancer survivors who may be at higher risk for osteopenia, and subsequently osteoporosis. Women with breast cancer who develop chemotherapy-induced ovarian failure should have their bone density monitored and treatments to attenuate bone loss should be evaluated.

Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study

2014 ◽  
Vol 25 (4) ◽  
pp. 1369-1378 ◽  
Author(s):  
P. Hadji ◽  
A. Kauka ◽  
M. Ziller ◽  
K. Birkholz ◽  
M. Baier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Bone Mineral ◽  
Premenopausal Women ◽  
Mineral Density ◽  
Adjuvant Therapies

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

2008 ◽  
Vol 9 (9) ◽  
pp. 840-849 ◽  
Author(s):  
Michael Gnant ◽  
Brigitte Mlineritsch ◽  
Gero Luschin-Ebengreuth ◽  
Franz Kainberger ◽  
Helmut Kässmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Endocrine Therapy ◽  
Bone Mineral ◽  
Early Stage ◽  
Premenopausal Women ◽  
Early Stage Breast Cancer ◽  
Mineral Density

Effect of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for breast cancer: the ProBONE II Study

2013 ◽  
Author(s):  
Peyman Hadji ◽  
Anette Kauka ◽  
Thomas Bauer ◽  
Katrin Birkholz ◽  
Monika Baier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Zoledronic Acid ◽  
Bone Mineral ◽  
Premenopausal Women ◽  
Mineral Density ◽  
Adjuvant Therapies
Sign in / Sign up

Export Citation Format

Share Document